Literature DB >> 9738683

Classifications of the International League Against Epilepsy: time for reappraisal.

J Engel1.   

Abstract

Recent advances in neurodiagnostic technology, new insights into fundamental neuronal mechanisms of epilepsy, and rapid developments in molecular genetics have greatly improved our understanding of epileptic seizures and epileptic disorders since 1981, when the current International Classification of Epileptic Seizures was adopted, and since 1989, when the International Classification of Epilepsies, Epileptic Syndromes, and Related Disorders was adopted. Although both have been universally accepted and have proven to be of considerable clinical value, it has become clear that more is needed for specific applications of growing importance, such as presurgical evaluation, clinical pharmacology trials, and epidemiological studies. Therefore, an International League Against Epilepsy (ILAE) task force has evaluated the need for revising our current classification and terminology and has begun developing four specific documents. The first is a descriptive terminology for ictal phenomena, incorporating some of the concepts included in the preceding paper by Dr. Hans Lüders; however, this will be a glossary, not a classification. The second is a classification of epileptic seizures based on known or presumed pathophysiological and anatomic substrates, to replace the current classification, which is based entirely on phenomenology. The third is a classification of epileptic syndromes and epileptic diseases, adapted from the current Classification of Epilepsies, Epileptic Syndromes, and Related Disorders, which will take into account the fact that disorders with unique etiologies, such as a single gene, should be considered diseases, and which will be reorganized for maximum practical application to differential diagnosis. The fourth is a new classification of functional disability due to seizures or epilepsy, based on a new impairment classification for neurological disorders being developed by the World Health Organization. Working groups are currently in the process of developing each of these documents, and their chairs would benefit from any comments or suggestions from those who ultimately will be using these systems of classification and terminology.

Entities:  

Mesh:

Year:  1998        PMID: 9738683     DOI: 10.1111/j.1528-1157.1998.tb01453.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

1.  [Ictal signs--cerebral localization and propagation].

Authors:  H Stefan
Journal:  Nervenarzt       Date:  2003-06       Impact factor: 1.214

2.  Correlation between Serum Level of Antiepileptic Drugs and their Side Effects.

Authors:  Abbashar Hussein; Amira Abdulgalil; Faroug Omer; Hassan Eltoum; Ahmed Hamad; Omer El-Adil; Bedraldin Mubarak; Mohmad Malkaldar; Iway Idris; Yasin Alwidaa; Esam Mahmoud
Journal:  Oman Med J       Date:  2010-01

Review 3.  State of the Art Approach to the Classification of Epileptic Seizures and Epilepsies.

Authors:  Ebru Barçin; Berrin Aktekin
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

4.  Neuroimaging in the definition and organization of the epilepsies: we're not there yet.

Authors:  Jason S Hauptman; Noriko Salamon; Gary W Mathern
Journal:  Epilepsia       Date:  2012-07       Impact factor: 5.864

Review 5.  Classification of seizures and epilepsy.

Authors:  James J Riviello
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

6.  Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Authors:  A Lothe; A Didelot; A Hammers; N Costes; M Saoud; F Gilliam; P Ryvlin
Journal:  Brain       Date:  2008-09-02       Impact factor: 13.501

7.  Strategies for promoting anti-seizure effects of hippocampal fetal cells grafted into the hippocampus of rats exhibiting chronic temporal lobe epilepsy.

Authors:  Muddanna S Rao; Bharathi Hattiangady; Kiranmai S Rai; Ashok K Shetty
Journal:  Neurobiol Dis       Date:  2007-05-23       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.